Header

In the News

07 Oct 2010 | Bloomberg

Amit Shabi comments on the Sanofi-Genzyme deal

Genzyme’s Defense Against Hostile Sanofi Takeover Is Time

"I am sure that Termeer will defend his shareholders until the last cent," said Amit Shabi, co-manager of Bernheim, Dreyfus & Co.'s Diva Synergy Fund, which owns Genzyme shares. "So we trust him. And he's right not talking to Sanofi at this price.“ Shabi, based in Paris, said he would "happily sell at $80, and with regrets at $76." At $69? "Never."

05 Oct 2010 | Bloomberg Businessweek

Amit Shabi comments on the Sanofi-Genzyme deal

Sanofi Takes $18.5 Billion Offer for Genzyme

“They had no choice but putting the offer on the table,” said Amit Shabi, co-manager of Bernheim, Dreyfus & Co.’s Diva Synergy Fund, which owns Genzyme shares, said of Sanofi. “They had no incentive to bump” up the price. “We think that they are going to bump at some point, to crack the opposition wall of shareholders.”

29 Sept 2010 | Bloomberg Businessweek

Amit Shabi comments on the Sanofi-Genzyme deal

Sanofi-Aventis Said to Weigh Higher Takeover Bid for Genzyme

"Sanofi needs a bump to start talks," said Amit Shabi, co -manager of Bernheim, Dreyfus & Co.'sDiva Synergy Fund,which ownsGenzyme shares.He estimated that the companywould have toraise the offer to $71 or $72 a share to get Genzyme to the negotiating table.

15 Sept 2010 | Bloomberg Businessweek

Lionel Melka comments on the Sanofi-Genzyme deal

Sanofi Says Genzyme Holders Expect Reasonable Price

Genzyme investors had been seeking at least $80 a share, based on potential revenue growth after production deficiencies responsible for drug shortages get resolved, shareholder Lionel Melka, the chief investment officer for Bernheim Dreyfus & Co., said this month.

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |  33 |  34